Indications (Approved Scope of Special Medical Case by Taiwan FDA)

Stage I to III Solid Tumors:
Lung cancer, liver cancer, breast cancer, ovarian cancer, colorectal cancer, gastric cancer, renal cancer, head and neck cancer.

Stage IV Solid Tumors:
Lung cancer, liver cancer, breast cancer, ovarian cancer, colorectal cancer, gastric cancer, renal cancer, head and neck cancer, pancreatic cancer, brain cancer, esophageal cancer, cervical cancer, endometrial cancer, skin cancer, prostate cancer.

Ideal Candidates

• Those with poor response to conventional cancer treatment or seeking immunotherapy combination
• Those post-surgery, radiation, or chemotherapy seeking to eliminate residual cancer cells and prevent recurrence
• Those prioritizing treatment safety and cell quality
• Those who have undergone precision screening confirming CIK therapy suitability
• Those willing to comply with treatment plans and participate in subsequent health management

Pre-Treatment Preparation
Physician Consultation and Assessment
Initial consultation will assess medical history, diagnosis, and treatment records to confirm suitability.

Prepare Relevant Documents
Please bring cancer medical records, examination reports, and medication history.

Blood Sample Collection
Professional staff will collect venous blood and isolate PBMC cells.

Understand Treatment Details
Learn about expected efficacy, estimated timeline (2-3 weeks cultivation), and potential side effects.

Physical and Mental Preparation
Maintain regular sleep schedule, balanced diet, and avoid excessive fatigue.

Warm Cancer Support Journey
Choosing Guangsheng means choosing a gentle yet steadfast force. Our CIK cell therapy is not just a technology—it's a warm choice in your cancer journey, becoming a trusted partner for you and your family.Differentiated Advantages and Professional Assurance

Patented Cell Cultivation Technology
Innovative culture environment enhances proliferation efficiency and activity stability—patent pending.

Dual-Certification Quality Control
Cell preparation facility GTP-certified; testing laboratory obtained TAF ISO/IEC 17025 in November 2024, with sterility, mycoplasma, and endotoxin testing protocols in place.

Complete Service Process
From screening assessment, cell collection, cultivation to post-infusion tracking recommendations—comprehensive healthcare.

Professional Medical Team Execution
Oncologists, immunology experts, and technical staff consistently execute treatment protocols.CIK Immune Cell Therapy—Harnessing Your Own Immune Power to Combat Cancer Threats

In the era of regenerative medicine, CIK (Cytokine-Induced Killer) immune cell therapy has become an important option for cancer adjunctive treatment, enhancing immune cell killing power through induced proliferation and activation.

What Is CIK Immune Cell Therapy?
Peripheral blood is drawn, and immune cells (mononuclear cells) are separated, proliferated, and activated in a laboratory compliant with Taiwan FDA's "Good Tissue Practice (GTP)" standards, then reinfused into the body for treatment. Activated CIK cells can actively identify and precisely kill cancer cells, strengthen the immune system, and help eliminate residual cancer cells.